search
Back to results

Exercise as Concussion Therapy Trial- 2 (ExACTT)

Primary Purpose

Mild Traumatic Brain Injury, Concussion, Mild

Status
Withdrawn
Phase
Phase 2
Locations
Australia
Study Type
Interventional
Intervention
Graded Exercise Therapy: ClearPlay(TM)
Sponsored by
ANSwers Neuroscience, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mild Traumatic Brain Injury focused on measuring Concussion, Mild Traumatic Brain Injury (mTBI), Exercise Therapy, Telemedicine, Therapeutic Intervention, Autonomic Function, Medical Device

Eligibility Criteria

14 Years - 45 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male or female subjects aged ≥14 to ≤45, able and willing to provide informed consent (≥18 years), or informed consent is obtained by the parent or legal guardian for minor subjects, with the minor providing age appropriate assent, according to local law and regulations;
  2. Subject is fluent in English, able to understand and agree to comply with protocol requirements, and complete all assessments;
  3. Subject has a history of recent concussion as diagnosed by a health care professional within 3 to 14 days of enrolment; Note: Concussion is defined as a head injury/blow to the head resulting in any of the following 3 signs and/or new symptoms: (1) amnesia for less than 24 hours; (2) Loss of consciousness for less than 30 minutes; (3) Glasgow Coma Scale score > = 13; (4) Dazed and Confused/bell rung; with at least 1 new symptom or augmentation of a previous symptom on the PCSS as compared with baseline at the time of enrolment, including: headaches, dizziness, fatigue, irritability, insomnia, difficulty concentrating, and/or memory difficulties; (5) The composite symptom score on the PCSS must be at least 3 points higher post-concussion than pre-concussion.
  4. Subject has daily access to the internet.

Exclusion Criteria:

  1. History of prior head injury as defined by:

    1. An injury/blow to the head within 12 months prior to screening with any associated residual symptoms;
    2. An injury/blow to the head within 3 months prior to screening diagnosed as a concussion;
    3. An injury/blow to the head within 3 months prior to screening with any of the following symptoms: amnesia, loss of consciousness, dazed and confused/bell rung;
  2. Evidence of blood or micro-hemorrhages on prior or current computed tomography scan or magnetic resonance imaging scan if obtained;
  3. Diagnosis of a neurological condition including the following: stroke, multiple sclerosis, epilepsy, brain tumor/cancer, encephalitis, dementia, movement disorder, or spontaneous nystagmus;
  4. Psychiatric history with any of the following:

    1. History of psychiatric hospitalization, history of legal trouble for violence;
    2. Requires psychotropic medication other than (1) stable dose of a selective serotonin reuptake inhibitors (SSRI) medication, or (2) stable dose of a tricyclic antidepressants (TCA) medication;
    3. Prior diagnosis of psychotic disorder, bipolar disorder, eating disorder, substance abuse disorder;
  5. Current use of a beta blocker;
  6. History of drug or alcohol dependency or abuse within a year before Screening, by self-report;
  7. Two or more the following cardiovascular risk factors:

    1. Prior diagnosis of, or currently taking medication for cardiovascular, metabolic or pulmonary conditions;
    2. Family history of myocardial infarction, coronary revascularization or sudden death before 55 years;
    3. Diagnosis of hypertension;
    4. Diagnosis of hyperlipidemia;
    5. Subjects with peripheral circulatory disorders;
  8. Subjects who are unable or unwilling to exercise for health or personal reasons;
  9. Subjects who have musculoskeletal injuries which could make exercise difficult or painful.

Sites / Locations

  • Royal Prince Alfred Hospital
  • University of Queensland
  • Alfred Health

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Graded Exercise

Passive Stretching

Arm Description

ClearPlay(TM): a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, will provide a telemetry-based graded exercise program for 20 minutes each day, identifying a heart rate target that will be advanced weekly for up to 8 weeks as symptoms resolve.

ClearPlay(TM): we have created a passive stretching program (placebo arm) downloadable to an Apple i-touch or i-phone device, that will provide a telemetry-based guided passive stretching program for 20 minutes each day for up to 8 weeks as symptoms resolve.

Outcomes

Primary Outcome Measures

ExACTT
The primary objective of the study is to compare the effects of graded exercise and passive stretching using ClearPlayTM (ANSwers Neuroscience Pty Ltd commercial mobile application) on recovery following mTBI in the Australian setting.

Secondary Outcome Measures

Full Information

First Posted
October 1, 2020
Last Updated
February 16, 2022
Sponsor
ANSwers Neuroscience, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04578743
Brief Title
Exercise as Concussion Therapy Trial- 2
Acronym
ExACTT
Official Title
Exercise as Concussion Therapy Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Withdrawn
Why Stopped
COVID-induced lockdowns.
Study Start Date
October 1, 2020 (Actual)
Primary Completion Date
September 30, 2021 (Actual)
Study Completion Date
September 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ANSwers Neuroscience, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a Phase 2, open-label study of a therapeutic intervention (graded exercise)compared to a reference therapy (passive stretching) in patients who have sustained mTBI. Subjects will be randomly assigned with a ratio of 1:1 to complete either graded exercise or passive stretching using a parallel-group design. The effects of graded exercise and passive stretching will be compared using ClearPlay© (ANSwers Neuroscience Pty Ltd commercial mobile application) The study will also validate the performance of two devices: ClearHeart©, ANSwers Neuroscience Pty Ltd commercial prototype for cold pressor testing, compared to ice bucket testing. ClearPlay©, ANSwers Neuroscience Pty Ltd commercial prototype based on the joint position error test to assess "whiplash".
Detailed Description
Study Type: Interventional Estimated Enrollment: 400 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Therapeutic Intervention, Open-Label Study to Compare the Efficacy and Safety of Graded Exercise Compared to Passive Stretching in Subjects Who Have Sustained a Mild Traumatic Brain Injury Estimated Study Start Date: October 1, 2020 Estimated Primary Completion Date: September 30, 2022 Estimated Study Completion Date: September 30, 2023

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mild Traumatic Brain Injury, Concussion, Mild
Keywords
Concussion, Mild Traumatic Brain Injury (mTBI), Exercise Therapy, Telemedicine, Therapeutic Intervention, Autonomic Function, Medical Device

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
This study is a Phase 2, open-label study of a therapeutic intervention (graded exercise) compared to a reference therapy (passive stretching) in patients who have sustained mTBI. Subjects will be randomly assigned with a ratio of 1:1 to complete either graded exercise or passive stretching using a parallel-group design.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Graded Exercise
Arm Type
Experimental
Arm Description
ClearPlay(TM): a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, will provide a telemetry-based graded exercise program for 20 minutes each day, identifying a heart rate target that will be advanced weekly for up to 8 weeks as symptoms resolve.
Arm Title
Passive Stretching
Arm Type
Experimental
Arm Description
ClearPlay(TM): we have created a passive stretching program (placebo arm) downloadable to an Apple i-touch or i-phone device, that will provide a telemetry-based guided passive stretching program for 20 minutes each day for up to 8 weeks as symptoms resolve.
Intervention Type
Device
Intervention Name(s)
Graded Exercise Therapy: ClearPlay(TM)
Intervention Description
ClearPlayTM; a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, that provides a telemetry-based graded exercise program that enables remote monitoring of symptoms.
Primary Outcome Measure Information:
Title
ExACTT
Description
The primary objective of the study is to compare the effects of graded exercise and passive stretching using ClearPlayTM (ANSwers Neuroscience Pty Ltd commercial mobile application) on recovery following mTBI in the Australian setting.
Time Frame
2 Years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female subjects aged ≥14 to ≤45, able and willing to provide informed consent (≥18 years), or informed consent is obtained by the parent or legal guardian for minor subjects, with the minor providing age appropriate assent, according to local law and regulations; Subject is fluent in English, able to understand and agree to comply with protocol requirements, and complete all assessments; Subject has a history of recent concussion as diagnosed by a health care professional within 3 to 14 days of enrolment; Note: Concussion is defined as a head injury/blow to the head resulting in any of the following 3 signs and/or new symptoms: (1) amnesia for less than 24 hours; (2) Loss of consciousness for less than 30 minutes; (3) Glasgow Coma Scale score > = 13; (4) Dazed and Confused/bell rung; with at least 1 new symptom or augmentation of a previous symptom on the PCSS as compared with baseline at the time of enrolment, including: headaches, dizziness, fatigue, irritability, insomnia, difficulty concentrating, and/or memory difficulties; (5) The composite symptom score on the PCSS must be at least 3 points higher post-concussion than pre-concussion. Subject has daily access to the internet. Exclusion Criteria: History of prior head injury as defined by: An injury/blow to the head within 12 months prior to screening with any associated residual symptoms; An injury/blow to the head within 3 months prior to screening diagnosed as a concussion; An injury/blow to the head within 3 months prior to screening with any of the following symptoms: amnesia, loss of consciousness, dazed and confused/bell rung; Evidence of blood or micro-hemorrhages on prior or current computed tomography scan or magnetic resonance imaging scan if obtained; Diagnosis of a neurological condition including the following: stroke, multiple sclerosis, epilepsy, brain tumor/cancer, encephalitis, dementia, movement disorder, or spontaneous nystagmus; Psychiatric history with any of the following: History of psychiatric hospitalization, history of legal trouble for violence; Requires psychotropic medication other than (1) stable dose of a selective serotonin reuptake inhibitors (SSRI) medication, or (2) stable dose of a tricyclic antidepressants (TCA) medication; Prior diagnosis of psychotic disorder, bipolar disorder, eating disorder, substance abuse disorder; Current use of a beta blocker; History of drug or alcohol dependency or abuse within a year before Screening, by self-report; Two or more the following cardiovascular risk factors: Prior diagnosis of, or currently taking medication for cardiovascular, metabolic or pulmonary conditions; Family history of myocardial infarction, coronary revascularization or sudden death before 55 years; Diagnosis of hypertension; Diagnosis of hyperlipidemia; Subjects with peripheral circulatory disorders; Subjects who are unable or unwilling to exercise for health or personal reasons; Subjects who have musculoskeletal injuries which could make exercise difficult or painful.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christina Master, MD
Organizational Affiliation
Children's Hospital of Philadelphia
Official's Role
Study Director
Facility Information:
Facility Name
Royal Prince Alfred Hospital
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Facility Name
University of Queensland
City
Brisbane
State/Province
Queensland
ZIP/Postal Code
4101
Country
Australia
Facility Name
Alfred Health
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia

12. IPD Sharing Statement

Learn more about this trial

Exercise as Concussion Therapy Trial- 2

We'll reach out to this number within 24 hrs